A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates.
Andrew W HahnGaniraju C ManyamBrian F ChapinMiao ZhangYao YuCurtis A PettawayLisly CheryLouis L PistersJohn F WardJustin R GreggJohn PapadopoulosAshish M KamatMarisa LozanoAnh HoangBradley BroomXuemei WangChad D HuffChristopher J LogothetisPatricia TroncosoPatrick G PiliéJohn W DavisPublished in: BJU international (2024)
Preoperative apalutamide did not reduce the aggregate postoperative radiation risk to the pre-specified threshold in unselected men with IRPCa. However, transcriptomic analysis identified key dysregulated pathways in tumours associated with adverse pathological outcomes and BCR, which warrant future study. Further investigation of preoperative therapy is underway for men with high-risk PCa.